North American Biologicals Acquires Pharmaceutical Product for Hepatitis from Abbott Laboratories

OCT 14 '92 08:26 PETER FEINSTEIM INC. P. 2
NEWS
Tie Quary Source
Contact for N'orth Amercan Biologicals: ' Zor Abbott.
David J. Gury, President?Traci Lanc
Alfred J. Fernandez, VP Finance Abbott Labc: torieC
North American Biologicals, Inc. [phone]
")'f5) 625-5303
Marcia A. Kean, Excc"ive VP
Feinstein Partners
p6t7) 577 3 0 G
NORTH AMERICAN BIOLOGICALS ACQUIRES PRA AJTICAL
PRODUCT FOR HEPATITIS FROM ABBOTT LABORATORIES
-- Abbott To Own 16% of Outstanding NABI Stock --
Miami, t.orida, October 8, 1992 -- North American Biologicals, Inc,
(NABI) (NASDAQ: NBIO) today announced it has entered the huntan
pharmaceutical market through the acquisition from Abbott Laboratorie~ of
H-BIG~, a proprietary plasma-based product for Hepatitis B. In the
transaction, Abbott will acquire two million NABI shares, or approximately
16% of the shares outstanding following the transaction. In addition, N4ly
has obtained from Abbott the exclusive right to acquire HIVIGM, an
experimental product which may prevent the transmission of AIDS from
HIV-positive mothers to unborn infants.
"We view our entry into the pharmaceutical market as a major milestonf in
NABI's evolution as a health care company," said David Gury, NA41.
Chairman, President, and CEO. "For more than 20 years, NABI has been a
leading provider of the plasma used by pharmaceutical companies to prodce
therapeutic products. Now, NABI is applying both its access to high-quality
human plasma and its expertise in testing plasma, to develop 2nd
commercialize its own proprietary immune globulin products for the
prevention and treatment of serious infections."
Immune globulin products are plasma-based products which contain a
natural range of antibodies produced in the body against a particular
infectious disease. The use of immune globulins has increased dramatically
in recent years, as scientists and clinicians have been able to identify and
access the desired antibodies to treat a range of conditions. The worldwide
market for immune globulin products is estimated at more than $500 million.
"With H-BIG~ as the first step, NABI is positioned to play an expanding role
in the fast-grcwing market for immune globulin 'i aeeut m. octuZs," Mr.

Gury added. e noted that in recent months ' as prepared for this
strategic P a --ding key executives r I managemint team
wftb pW ustry experience in - eh, rer alatory affairs and
16500 N.W. 15th Aven1
M ia m i, F lo r id a 3 3 1 6 5 5 7 1 0 9 5.0 2 8 1.0 0 3
[phone] Telefax: (30 5571095.0281.003